SABR as effective as surgery for early NSCLC?

Lobectomy is standard therapy for operable stage I non-small cell lung cancer (NSCLC), but the less invasive option of stereotactic ablative radiotherapy (SABR) could offer an alternative. A pooled analysis of data from two clinical trials shows that SABR achieved better than 90% of local tumor control in patients with stage I NSCLC.